Gut Instinct: Rebyota

November 2023

Rebyota (fecal microbiota, live-jslm), developed by Ferring Pharmaceuticals, is the first and only FDA-approved microbiota-based live biotherapeutic that works to prevent the recurrence of C. diff infection (CDI) at first recurrence. Launched in January 2023, the drug is for adults 18 years and older following antibiotic treatment for recurrent CDI. It is not indicated for the treatment of CDI.
Gut Instinct: Rebyota (